Minute Insight: Boston Scientific Walks Away From MI Tech Deal, Citing Regulatory Hurdles
Executive Summary
The Federal Trade Commission said it supports Boston Scientific’s decision to walk away from a planned $230m acquisition of Korea-based MI Tech. Boston Scientific said it could not obtain needed global regulatory approvals.
You may also be interested in...
Boston Scientific Adds More Non-Vascular Stents To MedSurg Business With MI Tech Acquisition
Boston Scientific will pay about $230m for 64% of Korea-based MI Tech, which developed the Hanarostent line of conformable, self-expanding metal stents for endoscopic and urologic applications.
Bayer Focuses On Medical Technology For Consumers With Precision Health Unit
German pharma giant says division will help people take control of their own health care with digital products.
Cardio Catch-Up: Two Studies Support Boston Scientific’s Subcutaneous ICD
Medtech Insight’s Cardiovascular Catch-Up highlights recent news on cardiovascular tech innovations that you may have missed. This edition covers the two clinical studies of Boston Scientific's Emblem MRI subcutaneous implantable cardioverter defibrillator.